Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:KRAS
|
| gptkbp:affects |
cell signaling pathways
|
| gptkbp:analyzes |
novel treatment options
|
| gptkbp:associated_with |
gptkb:healthcare_organization
disease progression metastasis poor response to therapy invasive cancer behavior chemotherapy resistance |
| gptkbp:caused_by |
uncontrolled cell growth
|
| gptkbp:discovered_by |
gptkb:1980s
|
| gptkbp:established |
apoptosis
|
| gptkbp:examines |
clinical research
biomarker studies |
| gptkbp:genetic_diversity |
point mutation
high in specific cancers |
| https://www.w3.org/2000/01/rdf-schema#label |
KRAS G12 D
|
| gptkbp:influences |
tumor microenvironment
drug response |
| gptkbp:is_a |
gptkb:Ninjutsu
driver mutation |
| gptkbp:is_aimed_at |
monoclonal antibodies
small molecule inhibitors KRAS inhibitors |
| gptkbp:is_analyzed_in |
genomic studies
|
| gptkbp:is_associated_with |
tumor heterogeneity
|
| gptkbp:is_characterized_by |
specific genetic alterations
|
| gptkbp:is_considered |
precision medicine approaches
|
| gptkbp:is_found_in |
tumor biopsies
human tumors |
| gptkbp:is_involved_in |
Ras signaling pathway
tumorigenesis angiogenesis |
| gptkbp:is_linked_to |
cell cycle dysregulation
poor prognosis immune evasion treatment resistance therapeutic challenges cellular metabolism changes |
| gptkbp:is_part_of |
cancer research initiatives
cancer genomics |
| gptkbp:is_popular_in |
common in cancer patients
|
| gptkbp:is_recognized_by |
genetic sequencing
|
| gptkbp:is_represented_in |
tumor cells
|
| gptkbp:is_studied_in |
clinical trials
therapeutic strategies preclinical models |
| gptkbp:location |
codon 12
|
| gptkbp:metabolism |
glycine to aspartic acid
|
| gptkbp:promotes |
cell proliferation
|
| gptkbp:research_focus |
cancer therapy
|